Garetosmab is named as a drug or biological intervention in 2 clinical trials in our USA, UK and China trial registers, none of which are currently recruiting. The lead sponsor is Regeneron Pharmaceuticals. Registered phases: Phase 3 and Phase 2. Conditions studied include Fibrodysplasia Ossificans Progressiva; Obesity.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05394116 | A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (ClinicalTrials.gov ↗) Fibrodysplasia Ossificans Progressiva |
Phase 3 | Active, closed |
| NCT06299098 | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation (ClinicalTrials.gov ↗) Obesity |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Fibrodysplasia Ossificans Progressiva | 1 |
| Obesity | 1 |
| Lead sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 2 |
| Register | Garetosmab trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in UK | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Garetosmab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Garetosmab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.